Physician profile
Supriya Narang
NPI 1083689293
$4,722.61
in general payments reported to CMS, 2019-2025
21 companies · $40.58 in 2025
The $40.58 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,548 · 2020: $880 · 2021: $1,102 · 2022: $587 · 2023: $565 · 2025: $40.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $719.73 | 2019-2023 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $651.45 | 2019-2022 | |
| Alkermes, INC. | $443.51 | 2019-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $410.57 | 2019-2023 | Austedo Xr, Austedo |
| Lundbeck LLC | $370.05 | 2019-2023 | Abilify Asimtufii, Abilify Maintena |
| Allergan, INC. | $351.15 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $344.82 | 2019-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $317.37 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $285.38 | 2021-2023 | Caplyta |
| Abbvie INC. | $268.67 | 2021-2023 | |
| Vanda Pharmaceuticals INC. | $152.97 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $80.29 | 2019-2022 | |
| Almatica Pharma LLC | $72.80 | 2021-2023 | Loreev Xr |
| Noven Therapeutics, LLC | $66.40 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.65 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $30.38 | 2020-2021 | |
| Alfasigma USA, INC. | $24.66 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.04 | 2025 | Cobenfy |
| Indivior INC. | $20.29 | 2023 | Perseris |
| Axsome Therapeutics, INC. | $16.54 | 2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $13.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supriya Narang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.